Refanezumab
Based on 1 Customer Validation
Refanezumab (GSK249320) is a brain-penetrant IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab has the potential for the enhancement of recovery of function poststroke.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 1233953-61-1
- Molecular Weight:148.28 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
Siglec-4a/MAG
Refanezumab by intravenous penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague Dawley rats (weight 361g)[1]
-
Dosage:10 mg/kg
-
Administration:IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses
-
Result:Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human MAG/Siglec-4a Protein (His Tag) can bind Refanezumab. The EC50 for this effect is 0.72 ng/mL.
Chemical Information
-
CAS No. 1233953-61-1
-
Appearance Liquid
-
Molecular Weight 148.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Refanezumab]
-
Synonyms
GSK249320
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21. [Content Brief]
[2]. B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)